Search Results

You are looking at 211 - 220 of 490 items for :

  • "paclitaxel" x
  • Refine by Access: All x
Clear All
Full access

Real-World Outcomes of Adjuvant Chemotherapy for Node-Negative and Node-Positive HER2-Positive Breast Cancer

Zachary Veitch, Omar F. Khan, Derek Tilley, Domen Ribnikar, Xanthoula Kostaras, Karen King, Patricia Tang, and Sasha Lupichuk

weekly paclitaxel, 2 single-arm phase II trials evaluated the utility of short-course docetaxel/cyclophosphamide (DCH for 4 cycles) 13 or paclitaxel (weekly for 12 weeks) 14 in combination with trastuzumab for low-risk HER2+ breast cancer. Both trials

Full access

Oncogenic Addiction to ERBB2 Signaling Predicts Response to Trastuzumab in Urothelial Cancer

Michael Karass, Rohan Bareja, Ethan Shelkey, Panagiotis J. Vlachostergios, Brian D. Robinson, Francesca Khani, Juan Miguel Mosquera, Douglas S. Scherr, Andrea Sboner, Scott T. Tagawa, Ana M. Molina, Olivier Elemento, David M. Nanus, and Bishoy M. Faltas

treated with trastuzumab, paclitaxel, carboplatin, and gemcitabine, 14 ERBB2 overexpression by IHC, gene amplification in the tumor by FISH, or presence in serum for extracellular ERBB2 domain testing by quantitative enzyme-linked immunosorbent assay was

Full access

Carcinosarcomas (Malignant Mixed Müllerian Tumor) of the Uterus: Advances in Elucidation of Biologic and Clinical Characteristics

Lauren E. Kernochan and Rochelle L. Garcia

Edited by Kerrin G. Robinson

chemotherapy regimens containing platinum . Gynecol Oncol 2008 ; 108 : 136 – 140 . 28 Homesley HD Filiaci V Markman M . Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group

Full access

Comparative Effectiveness of Carboplatin/Pemetrexed With Versus Without Bevacizumab for Advanced Nonsquamous Non–Small Cell Lung Cancer

Stephen J. Bagley, Suzanna Talento, Nandita Mitra, Neal J. Meropol, Roger B. Cohen, Corey J. Langer, and Anil Vachani

randomized phase III ECOG 4599 trial, which demonstrated an OS advantage associated with addition of bevacizumab to carboplatin/paclitaxel. 11 Although results of the PointBreak trial showed that carboplatin/pemetrexed/bevacizumab yielded similar OS compared

Full access

Oncology Research Program

Comprehensive Cancer Center-James Cancer Hospital and Solove Research Institute Patients receive paclitaxel albumin-stabilized nanoparticle formulation intravenously over 30 minutes and carboplatin intravenously over 1 to 2 hours on day 1. Treatment repeats

Full access

NCCN Guidelines® Updates

preoperative neoadjuvant paclitaxel, ifosfamide, and cisplatin ( TIP ). Stable or responding patients should then undergo surgical resection consolidative surgery ...” For “Preferred radiosensitizing agents and combinations,” the heading was clarified

Full access

NCCN News

addition of bevacizumab to upfront therapy with carboplatin/paclitaxel or as maintenance therapy at this time. The NCCN panel encourages participation in ongoing clinical trials that are further investigating the role of antiangiogenesis agents in the

Full access

Anaplastic Thyroid Carcinoma, Version 2.2015

Robert I. Haddad, William M. Lydiatt, Douglas W. Ball, Naifa Lamki Busaidy, David Byrd, Glenda Callender, Paxton Dickson, Quan-Yang Duh, Hormoz Ehya, Megan Haymart, Carl Hoh, Jason P. Hunt, Andrei Iagaru, Fouad Kandeel, Peter Kopp, Dominick M. Lamonica, Judith C. McCaffrey, Jeffrey F. Moley, Lee Parks, Christopher D. Raeburn, John A. Ridge, Matthew D. Ringel, Randall P. Scheri, Jatin P. Shah, Robert C. Smallridge, Cord Sturgeon, Thomas N. Wang, Lori J. Wirth, Karin G. Hoffmann, and Miranda Hughes

approved by the FDA for ATC. 31 Single-agent paclitaxel may benefit some newly diagnosed patients; increased survival has been reported in patients with stage IVB disease. 77 – 79 If weekly paclitaxel is used, the ATA guidelines recommend using paclitaxel

Full access

Multimodality Approaches for the Curative Treatment of Esophageal Cancer

Raymond Jang, Gail Darling, and Rebecca K.S. Wong

with clinical stage T1N1 or T2–3N0–1 disease were eligible, and were randomized to either 41.4 Gy of radiotherapy over 5 weeks with concurrent weekly carboplatin (area under the curve, 2) and paclitaxel (50 mg/m 2 ) followed by surgery, or to surgery

Full access

NCCN Guidelines® Insights: Squamous Cell Skin Cancer, Version 1.2022

Featured Updates to the NCCN Guidelines

Chrysalyne D. Schmults, Rachel Blitzblau, Sumaira Z. Aasi, Murad Alam, James S. Andersen, Brian C. Baumann, Jeremy Bordeaux, Pei-Ling Chen, Robert Chin, Carlo M. Contreras, Dominick DiMaio, Jessica M. Donigan, Jeffrey M. Farma, Karthik Ghosh, Roy C. Grekin, Kelly Harms, Alan L. Ho, Ashley Holder, John Nicholas Lukens, Theresa Medina, Kishwer S. Nehal, Paul Nghiem, Soo Park, Tejesh Patel, Igor Puzanov, Jeffrey Scott, Aleksandar Sekulic, Ashok R. Shaha, Divya Srivastava, William Stebbins, Valencia Thomas, Yaohui G. Xu, Beth McCullough, Mary A. Dwyer, and Mai Q. Nguyen

regional or distant metastatic CSCC. Those most commonly used are cisplatin, carboplatin, and 5-FU, either as monotherapy or combination regimens. 66 – 76 For the 2022 update, the panel voted to include carboplatin ± paclitaxel under options useful in